BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $100 from $81 and keeps a Buy rating on the shares. Eli Lilly (LLY) on Friday shared Phase 3 ADapt data, showing a majority of atopic dermatitis patients who discontinued Dupixent went on to achieve EASI-75 with lebrikizumab at 16 weeks and an even larger proportion at 24 weeks, the analyst tells investors in a research note. With impressive post-Dupixent efficacy confirmed, BTIG thinks the IL-13 class could grow even larger than prior expectations, reading through positively to Apogee’s APG777.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APGE:
- Apogee Therapeutics Unveils Promising Phase 1 Trial Results
- Apogee Therapeutics announces updated results from Phase 1 trial of APG777
- Apogee Therapeutics names Jeff Hartness as Chief Commercial Officer
- Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
